Department of Health and Human Services
Public Health Service
November 25, 2002
CERTIFIED MAIL, RETURN RECEIPT REQUESTED
CEO & President
Par Deus, Inc.
2 Breeze Ave, Ste 108
Venice, CA 90291
Ref. No. W/L 10-03
Dear Sir or Madam:
This letter is written in reference to your firm’s marketing of the products 4-ADerm Topical Anabolic Gel, Nor-ADerm Topical Anabolic Gel, and ONE+ Topical Anabolic Gel, each of which contains androstenediol. Your Internet website, http://www.mindandmuscle.net, from which these products may be ordered, states for example, “the sustained release action inherent to topicals ensures that androgen levels remain continuously elevated, day and night, aiding your muscle-building efforts long after other products have quit…”
The above products are topically applied for transdermal absorption to achieve their intended effect. As such, these products cannot be dietary supplements because they are not intended for ingestion since they are topical products that are intended to bypass the alimentary canal by direct absorption through the skin. The Act defines the term, “dietary supplement” in Section 201(ff)(2)(A)(i) to mean a product that is “…intended for ingestion…” Consequently, a product that is not intended for ingestion cannot meet the definition of “dietary supplement”.
Based on their intended uses to affect the structure or any function of the body of man, these products are drugs within the meaning of Section 201(g) of the Federal Food, Drug, and Cosmetic Act (the Act). As drugs, the labeling claims made for these products subject them to the requirements for new drugs [Section 201(p) of the Act] because there is no evidence that these products are generally recognized as safe and effective for their claimed uses. Further, all transdermal drug delivery products are new drugs because of the newness of the dosage or the method or duration of administration or application suggested in the labeling (See Title 21 of the Code of Federal Regulations, Part 310.3). Under Section 505 of the Act, a “new drug” may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved new drug application (NDA) is in effect for such drug. Because your products are not the subjects of approved NDA’s, they may not be marketed in the United States and their continued distribution violates Section 505 of the Act.
This letter is not intended to be an all-inclusive review of your Internet website nor all labeling and products your firm markets. The violation described above is not intended to be an all inclusive list of violations concerning your firm and its products. It is your responsibility to ensure that all products marketed by your firm, including other products containing androstenediol, are in compliance with the Act and its implementing regulations.
We request that you take prompt action to correct these violations. Failure to promptly correct violations may result in enforcement action being initiated by the FDA without further notice. The Act provides for seizure of illegal products and for injunction against the manufacturer and/or distributor of illegal products.
Please notify this office in writing within fifteen (15) working days of receipt of this letter as to the specific steps you have taken to correct the stated violations. You should also include an explanation of each step being taken to identify and make corrections to assure similar violations will not recur. If corrective action cannot be completed within fifteen (15) working days, state the reason for the delay and the time within which corrections will be implemented.
If you have any questions regarding this letter, please contact Mr John Stamp, Compliance Officer, at 949-798-7764. Your written reply should be addressed to:
Thomas L. Sawyer
Director of Compliance
Food and Drug Administration
19900 MacArthur Blvd, Ste 300
Irvine, CA 92612
Alonza E. Cruse
cc: CEO & President
Par Deus, Inc.
13821 SE 114th
Oklahoma City, OK 73165
This page was posted on May 4, 2006.